• Gerhard Bauer, PhD, has been named to be corporate senior vice president and senior vice president, Global Operations & Engineering, at Bausch & Lomb (Rochester, New York), as of May 1. Bauer has been B&L vice president of Global Operations & Engineering for Europe since 2001. He succeeds Dwain Hahs, 53, who has been named B&L senior vice president and president - Asia Region. Bauer has been with Bausch & Lomb for 14 years. Hahs was most recently B&L corporate senior vice president and senior vice president - Global Operations & Engineering, a post that Gerhard Bauer, PhD, now assumes. Bauer has been B&L vice president of Global Operations & Engineering for Europe since 2001.
• CardioTech International (Wilmington, Massachusetts), a manufacturer of devices for treating cardiovascular disease, reported that Michael Adams will be re-joining the company as vice president of regulatory affairs and business development. Adams has been a positions with CardioTech International., Cytyc, CR Bard, Millipore and E I DuPont. Member of the CardioTech Board since 1999. Previously, Adams was the Vice President of New Ventures for PLC Medical Systems where he was responsible for all regulatory and product development activities. Prior to that Adams held executive positions with CardioTech, Cytyc, CR Bard, Millipore and E I DuPont. CardioTech is conducting human clinical trials with CardioPass, a synthetic coronary artery bypass graft, and has partnered to develop a drug-eluting stent.
• Todd Stallings has been promoted from clinical trial manager to vice president, Clinical Operations, at Corautus Genetics (Atlanta), a developer of gene transfer therapy for cardiovascular applications.
• Jeffrey Cossman, MD, has been named chief scientific officer for theCritical Path Institute (C-Path; Tucson, Arizona). The appointment will include establishment of a C-Path satellite facility in the Washington area. Cossman will provide overall scientific leadership in support of the FDA Critical Path Initiative in the establishment of partnerships to accelerate the realization of personalized medicine. Cossman has served as the Oscar Benwood Hunter Professor and Chairman of the Department of Pathology at Georgetown University and as a senior scientist at the NCI-NIH. C-Path was established in 2005 as a publicly funded non-profit research and education institute to facilitate collaboration among its founding partners, the FDA, the University of Arizona, and SRI International.
• Arthur Holden has been appointed senior vice president of corporate and market development of Illumina (San Diego). Holden was most recently chairman and CEO of First Genetic Trust and the company's principal founder. Illumina is developing next-generation tools that permit large-scale analysis of genetic variation and function.
• Martin Crous, PhD, has joined Innovasis (Salt Lake City, Utah), a manufacturer of spinal implants, as vice president of sales and marketing. Crous has worked for companies such as Synthes and as head of Medtronic Sofamor Danek for Africa. Innovasis offers a spinal product line with implants and instruments that address the major pathologies and focus areas of traditional spinal surgery.
• Uroplasty (Minneapolis) reported the addition of three regional managers to support U.S. sales expansion. Rob Crohn has been named northeast regional sales manager; Craig Winslow will serve as western regional sales manager; and Sid Stark will serve as southeast regional manager. Uroplasty and its wholly owned subsidiaries develop products for the treatment of voiding dysfunctions, including urinary and fecal incontinence, overactive bladder and vesicoureteral reflux.